PLK1 and neoplasm: In summary, our pre-clinical data found that targeting Plk1 by onvansertib demonstrated great potency in inhibiting cellular proliferation, inducing G2 cell cycle arrest and apoptosis, increasing cellular stress, impairing cellular adhesion, and reducing tumor growth in EC cells and the LKB1fl/flp53fl/fl mouse model of endometrioid EC.